Laigo Bio BV

Based in Utrecht, Netherlands, and founded in 2025, Laigo Bio BV engages in the development of advanced therapies focused on targeted protein degradation, utilizing their proprietary SureTACs platform to enhance cancer treatment outcomes. Laigo Bio BV specializes in innovative therapeutic solutions, particularly in oncology. The company was founded in Utrecht, Netherlands. In March 2026, Laigo Bio BV raised EUR 5.

5 million in seed funding co-led by Biovance Capital and Kurma Partners, with participation from Curie Capital, Argobio SAS, Eurazeo, and Cancer Research Horizons. Angelini Ventures, Oncode Institute, and ROM Utrecht Region also participated in the round. Laigo Bio specializes in targeted protein degradation through its proprietary technology platform known as SureTACs (Surface Removal Targeting Chimeras). The core product offering involves the development of bispecific antibodies that facilitate the precise removal of disease-causing proteins from cell surfaces, particularly in oncology and autoimmune diseases.

By leveraging an understanding of E3 ligase function, Laigo Bio creates selective therapies that target undruggable proteins, enhancing tumor-tissue specificity and improving therapeutic outcomes. The company's innovative approach is aimed at addressing unmet needs in cancer treatment and expanding into other therapeutic areas, such as immunology and neuroinflammation. Currently, Laigo Bio’s products are positioned for markets across Europe and North America, catering to pharmaceutical and biotechnology companies seeking advanced therapeutic solutions. Laigo Bio has secured EUR 11.

5 million in Seed financing to support the development of its SureTAC technology platform, which is anticipated to drive its revenue through partnerships and collaborations with research institutions and healthcare providers. The company’s revenue model is based on strategic partnerships, where it collaborates with large pharmaceutical firms for the clinical advancement of its novel therapies. These partnerships often involve milestone payments and royalties based on the commercial success of the developed therapies. Given the focus on precision medicine, Laigo Bio's transactions are likely to center on licensing agreements and collaborative research initiatives, allowing it to monetize its proprietary technologies as they progress through clinical trials and into market-ready products.

The emphasis on first-in-class therapies positions Laigo Bio to generate revenue streams through both direct B2B transactions and potential future product sales following successful commercialization. The company plans to utilize the March 2026 funding to speed up development of SureTACs programs in oncology and advance candidates in auto-immunity, immunology, and graft rejection.